NeutraKine® IL-17A Monoklonaler Antikörper

NeutraKine® IL-17A Monoklonal Antikörper für Neutralization, ELISA

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human

Anwendung

Neutralization, Cell treatment, ELISA

Konjugation

Unkonjugiert

CloneNo.

1F3E3

Kat-Nr. : 69021-1-Ig

Synonyme

CTLA 8, CTLA8, IL 17, IL 17A, IL17, IL-17, IL17A, IL-17A, interleukin 17A, NeutraKine® IL-17A



NeutralizationHT-1080 cell

Produktinformation

69021-1-Ig bindet in Neutralization, Cell treatment, ELISA NeutraKine® IL-17A und zeigt Reaktivität mit human

Getestete Reaktivität human
In Publikationen genannte Reaktivitäthuman
Wirt / Isotyp Maus / IgG1
Klonalität Monoklonal
Typ Antikörper
Immunogen human Humankine IL-17A protein HZ-1113
Vollständiger Name interleukin 17A
Gene symbol IL17A
Gene ID (NCBI) 3605
Konjugation Unkonjugiert
Form Lyophilized Powder
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer Sterile PBS.
Endotoxin<0.1 EU/μg
WiederherstellungThis product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
Stability and StorageLyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Hintergrundinformationen

IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.

This antibody can be used to neutralize the bioactivity of IL-17A.

Publikationen

SpeciesApplicationTitle
Neutralization

Int J Chron Obstruct Pulmon Dis

IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD

Authors - Danyang Li
humanCell treatment

JCI Insight

Targeting mTOR with a sirolimus-eluting airway stent reduces pro-fibrotic TH17-cells and inhibits laryngotracheal stenosis

Authors - Kevin M Motz